PESI and simplified PESI (sPESI) score (also searched with possessive/alternate eponym spelling where applicable, ICD-10: I26.9) is a clinically validated prognostic tool designed to estimate 30-day all-cause mortality in patients diagnosed with acute pulmonary embolism (PE) 1. By integrating demographic characteristics, physiological parameters, and pre-existing comorbid conditions into a standardized point system, the original Pulmonary Embolism Severity Index (PESI) and its streamlined derivative (sPESI) enable clinicians to objectively categorize patients into low-risk and high-risk categories 1,2. This risk stratification is critical in guiding disposition decisions—specifically identifying hemodynamically stable patients who can be safely discharged for outpatient management or early home care, thereby optimizing inpatient bed utilization and reducing healthcare costs without compromising patient safety 1,2.

Etiology & Risk Factors

  • Venous Thromboembolism (VTE) Background: Pulmonary embolism arises predominantly from thrombi originating in the deep venous system of the lower extremities (deep vein thrombosis, DVT), which dislodge and embolize through the right heart chambers into the pulmonary arterial tree.
  • Virchow’s Triad Determinants: Hypercoagulable states (malignancy, factor V Leiden mutation, oral contraceptive use, pregnancy, antiphospholipid syndrome), endothelial injury (trauma, central venous catheterization, surgery), and venous stasis (immobilization, prolonged travel, heart failure, obesity) directly amplify PE incidence and severity.
  • Comorbid Vulnerabilities in PESI Scoring: Pre-existing chronic conditions—specifically active cancer, chronic heart failure, and chronic pulmonary disease—are weighted heavily in both PESI and sPESI scoring systems because they diminish baseline physiological reserve, rendering the patient exceptionally susceptible to the acute haemodynamic insult of right ventricular afterload mismatch 1,2.
  • Advanced Age: Age acts as a continuous and independent risk factor for adverse outcomes in PE, reflecting cumulative vascular senescence, diminished cardiopulmonary reserve, and a higher prevalence of occult comorbidities 1.

Pathophysiology

Acute pulmonary embolism initiates a cascade of mechanical and functional derangements within the cardiopulmonary system. Obstruction of the pulmonary arterial bed by thrombi leads to an immediate increase in pulmonary vascular resistance (PVR). As PVR rises, right ventricular (RV) afterload increases precipitously. To maintain cardiac output, the right ventricle dilates and increases its contractile force; however, this results in heightened myocardial oxygen demand and concomitant subendocardial ischaemia. The resulting RV strain impairs left ventricular (LV) filling via ventricular interdependence (septal bowing into the left ventricle), which subsequently reduces systemic cardiac output and systemic blood pressure. Neurohormonal activation, marked by the release of catecholamines, natriuretic peptides (NT-proBNP), and cardiac troponins, further exacerbates myocardial injury and systemic vasoconstriction. Concurrently, ventilation-perfusion (V/Q) mismatch develops due to unperfused ventilated lung zones and hypoxic pulmonary vasoconstriction, leading to systemic hypoxaemia. The PESI and sPESI scoring systems capture the systemic footprint of this pathophysiological cascade by evaluating markers of organ hypoperfusion (hypotension, tachycardia, hypoxaemia) and baseline frailty (age, cancer, cardiopulmonary comorbidities) to predict 30-day mortality 1,2.

PESI and simplified PESI (sPESI) score — Pathophysiological Cascade & Clinical Flowchart 1 Acute Pulmonary Embolism Thromboembolic occlusion ofومي the pulmonary arterial bed increases right ventricular afterload. 2 Haemodynamic Compromise Right ventricular strain, ischaemia, and neurohormonal activation lead to systemic instability. 3 Systemic Stress & Comorbidities Age, underlying cardiopulmonary disease, and cancer compound physiological vulnerability. 4 Risk Stratification Deficit Clinical scoring systems like PESI and sPESI quantify 30-day mortality risk to direct appropriate triage. 5 Outpatient vs. Inpatient Triage Low-risk scores permit safe ambulatory management, whereas high scores mandate intensive hospital monitoring.

Clinical Presentation & Classic Clinical Signs

  • History & Cardinal Symptoms: Patients frequently present with sudden-onset, unexplained dyspnea at rest or upon minimal exertion, pleuritic chest pain exacerbated by deep inspiration, and cough. Massive PE may manifest with syncope, presyncope, severe central cyanosis, or acute cardiovascular collapse. Less commonly, patients report haemoptysis due to pulmonary infarction or unilateral lower extremity swelling and tenderness indicative of a concurrent DVT.
  • Physical Examination & Named Clinical Signs: Examination typically reveals acute tachypnea (respiratory rate >20 breaths/min) and tachycardia (heart rate ≥110 bpm in higher-risk strata). Cardiovascular examination may demonstrate an accentuated pulmonic component of the second heart sound (P_2), a right-sided third heart sound (S_3 gallop), elevated jugular venous pressure (JVP), a parasternal lift, or a tricuspid regurgitation murmur. Pulmonary examination is frequently clear to auscultation but may reveal crackles or a pleural friction rub. Lower extremity inspection must actively screen for asymmetric calf swelling, pitting edema, or palpable cord-like veins suggestive of DVT.

Diagnostic Workup & Interpretation (Laboratory, Imaging & ECG/Pathology)

Diagnostic Modality / Test Expected Clinical & Radiological / Laboratory Finding
Gold-Standard InvestigationComputed tomography pulmonary angiography (CTPA) demonstrating sharp, non-enhancing filling defects within the main, lobar, segmental, or subsegmental pulmonary arteries.
Laboratory PanelElevated plasma D-dimer (useful for ruling out PE in low-probability outpatients using age-adjusted thresholds), elevated cardiac troponins (hs-cTnT or cTnI indicating myocardial strain), and elevated NT-proBNP reflecting right ventricular wall stretch. Arterial blood gas analysis characteristically reveals acute respiratory alkalosis with an increased alveolar-arterial (A-a) oxygen gradient and hypoxaemia.
Imaging / Radiology (X-ray, US, CT, MRI)Chest radiography is often normal or shows non-specific abnormalities (atelectasis, pleural effusion, elevated hemidiaphragm, Westermark sign, or Hampton's hump). Compression ultrasonography of the lower extremities frequently reveals non-compressible deep veins indicative of DVT. Echocardiography demonstrates RV dilation, hypokinesis, McConnell's sign (free wall akinesia with apical sparing), and flattening of the interventricular septum.
ECG / Histopathology / ProceduralElectrocardiogram (ECG) commonly exhibits sinus tachycardia. Classic findings in significant strain include the S_1Q_3T_3 pattern (deep S in lead I, Q in lead III, inverted T in lead III), incomplete or complete right bundle branch block (RBBB), and T-wave inversions in leads V_1–V_4. Ventilation-perfusion (V/Q) scintigraphy reveals mismatched segmental perfusion defects in patients unable to receive iodinated contrast.

Staging, Classification & Clinical Scoring Systems

Criterion / Stage / Score Component Clinical Threshold, Points & Management Implication
Original PESI ComponentsIncorporates 11 clinical variables: Age (age in years), Male sex (+10 pts), Cancer (+30 pts), Heart failure (+10 pts), Chronic pulmonary disease (+10 pts), Pulse rate ≥110 bpm (+20 pts), Systolic blood pressure <100 mmHg (+30 pts), Respiratory rate >30 breaths/min (+20 pts), Temperature <36°C (+20 pts), Altered mental status (+60 pts), Arterial oxyhaemoglobin saturation <90% (+20 pts).
Original PESI Risk ClassesClass I (≤65 pts: very low 30-day mortality, 0-1.6%); Class II (66-85 pts: low mortality, 1.7-3.5%); Class III (86-105 pts: intermediate mortality, 3.2-7.1%); Class IV (106-125 pts: high mortality, 4.0-11.4%); Class V (>125 pts: very high mortality, 10.0-24.5%). Classes I and II are candidates for outpatient care.
Simplified PESI (sPESI) ComponentsStreamlined to 6 variables, assigning 1 point each: Age >80 years (+1 pt), History of cancer (+1 pt), Chronic cardiopulmonary disease (+1 pt), Heart rate ≥110 bpm (+1 pt), Systolic blood pressure <100 mmHg (+1 pt), Arterial oxyhaemoglobin saturation <90% (+1 pt).
Simplified PESI (sPESI) InterpretationA total score of 0 points designates the patient as low risk (approximate 30-day mortality rate of 1.0%), supporting early discharge and ambulatory/outpatient management. A score of ≥1 point designates the patient as high risk for 30-day adverse outcomes, mandating hospital admission for inpatient monitoring, risk stratification with biomarkers/echocardiography, and therapeutic anticoagulation.

Differential Diagnosis

Differential Condition Distinguishing Clinical, Biochemical & Imaging Features
Acute Coronary Syndrome (ACS)Presents with chest pain and dyspnea, but typically exhibits ischemic ECG changes (ST-segment elevation or depression, dynamic T-wave inversions), localized wall motion abnormalities on echocardiography, and elevated cardiac troponins without typical VTE risk factors or V/Q mismatch.
Decompensated Heart FailureCharacterized by progressive dyspnea, orthopnea, paroxysmal nocturnal dyspnea, and bilateral pedal edema. Chest radiography demonstrates pulmonary venous congestion, cardiomegaly, and Kerley B lines. CTPA excludes acute pulmonary arterial filling defects.
Pneumonia / Lower Respiratory Tract InfectionAccompanied by productive cough, fever, purulent sputum, and localized focal consolidation on chest radiography or CT. Inflammatory markers (leukocytosis, procalcitonin, CRP) are markedly elevated, and D-dimer is typically less disproportionately raised.
Aortic DissectionPresents with sudden-onset, severe "tearing" chest or back pain often radiating to the interscapular region, frequently accompanied by pulse deficits or focal neurological deficits. Diagnosed via contrasted CT aortography showing an intimal flap.

Management & Treatment Protocol

  • Initial Stabilization & Resuscitation: Immediate assessment of airway, breathing, and circulation. Administer supplemental oxygen if oxyhaemoglobin saturation drops below 92%, aiming to correct hypoxaemia. For patients exhibiting haemodynamic instability (persistent hypotension with systolic blood pressure <90 mmHg or vasopressor requirement), aggressive fluid resuscitation should be minimized; instead, initiate vasopressor support with norepinephrine (infusion titrated from 2 to 20 mcg/min) to maintain adequate mean arterial pressure and coronary perfusion.
  • First-Line Medical / Pharmacological Therapy (with exact adult dosing): For low-risk patients identified by PESI or sPESI scores (sPESI = 0) who are suitable for outpatient care, initiate direct oral anticoagulants (DOACs) without delay:
    • Rivaroxaban: 15 mg orally twice daily for the first 21 days, followed by 20 mg orally once daily for maintenance.
    • Apixaban: 10 mg orally twice daily for the first 7 days, followed by 5 mg orally twice daily thereafter.
    Alternatively, initiate parenteral anticoagulation overlap with low-molecular-weight heparin (LMWH, e.g., enoxaparin 1 mg/kg subcutaneously every 12 hours or 1.5 mg/kg subcutaneously once daily) or unfractionated heparin (UFH intravenous infusion targeting an activated partial thromboplastin time [aPTT] 1.5 to 2.5 times control) transitioned to vitamin K antagonists (warfarin initiated at 5 mg daily, adjusted to achieve a target INR of 2.0 to 3.0). Standard duration of anticoagulation for provoked PE is a minimum of 3 months; unprovoked PE warrants evaluation for extended or indefinite therapy.
  • Surgical / Interventional Indications: Systemic thrombolysis (e.g., alteplase 100 mg intravenously over 2 hours) is reserved for high-risk PE presenting with cardiogenic shock or sustained hypotension. Catheter-directed thrombolysis, mechanical thrombectomy, or surgical embolectomy are indicated for massive PE when systemic thrombolysis is contraindicated or fails.

Complications & Prognosis

  • Acute Complications: Right ventricular failure, cardiogenic shock, recurrent pulmonary embolism, fatal cardiac arrest, and systemic hypoxemic encephalopathy.
  • Chronic Complications: Chronic thromboembolic pulmonary hypertension (CTEPH), manifesting months to years after the initial event with progressive dyspnea on exertion and right heart failure, alongside post-PE syndrome characterized by persistent functional limitations, exercise intolerance, and psychological distress.
  • Prognostic Determination: The prognosis of acute PE is intimately linked to baseline physiological status and right ventricular function. Patients classified as low risk by the simplified PESI score (sPESI = 0) exhibit an exceptionally favorable prognosis, with a 30-day all-cause mortality rate around 1%, supporting safe early discharge 1,2. Conversely, patients with elevated sPESI scores, right ventricular strain on imaging, or elevated cardiac biomarkers face a significantly elevated risk of early mortality and require inpatient admission, close monitoring, and potential escalation of therapy 1,2.